The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11148 malaria professionals are enjoying the free benefits of MalariaWorld today


NOT open Access | Partial protection against P. vivax infection diminishes hypnozoite burden and blood-stage relapses

May 19, 2021 - 13:32 -- NOT Open Access
Schäfer C, Dambrauskas N, Sather DN, et al.
Cell Host Microbe. 2021 May 12;29(5):752-756.e4

Latent forms of Plasmodium vivax, called hypnozoites, cause malaria relapses from the liver into the bloodstream and are a major obstacle to malaria eradication. To experimentally assess the impact of a partially protective pre-erythrocytic vaccine on reducing Plasmodium vivax relapses, we developed a liver-humanized mouse model that allows monitoring of relapses directly in the blood. We passively infused these mice with a suboptimal dose of an antibody that targets the circumsporozoite protein prior to challenge with P. vivax sporozoites.

Not Open Access | Efficacy and Safety of the Mosquitocidal Drug Ivermectin to Prevent Malaria Transmission After Treatment: A Double-Blind, Randomized, Clinical Trial

January 14, 2015 - 18:12 -- NOT Open Access
André Lin Ouédraogo, Guido J. H. Bastiaens, Teun Bousema, et al.
Clin Infect Dis. (2015) 60 (3): 357-365

Although we found no evidence that IVM reduced Plasmodium infection rates among surviving mosquitoes, the mosquitocidal effect of AL-IVM1 and AL-IVM2 resulted in 27% and 35% reductions, respectively, in estimated malaria transmission potential during the first week after initiation of treatment.

Subscribe to RSS - malara